1226781-80-1

Basic information

• Product Name: 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole
• Synonyms: 2,4,5,6-tetrahydro-2-(methylsulfonyl)-Pyrrolo[3,4-c]pyrazole;Pyrrolo[3,4-c]pyrazole, 2,4,5,6-tetrahydro-2-(methylsulfonyl)-
• CAS NO: 1226781-80-1
• Molecular Formula: C₆H₉N₃O₂S
• Molecular Weight: 187.21956
• EINECS: -0
• Mol File: 1226781-80-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 377.5±34.0 °C(Predicted)
• Appearance: /
• Density: 1.67±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 6.41±0.20(Predicted)
• CAS DataBase Reference: 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole(1226781-80-1)
• EPA Substance Registry System: 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole(1226781-80-1)

Safety Data

• Hazardous Substances Data: 1226781-80-1(Hazardous Substances Data)

Usage

Description

2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole is a chemical compound with a unique structure that features a methylsulfonyl group and a tetrahydropyrrolo[3,4-c]pyrazole core. 2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole has potential applications in the pharmaceutical industry due to its specific properties and reactivity.

Uses

Used in Pharmaceutical Industry:
2-(Methylsulfonyl)-2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole is used as a reagent for the development of dipeptidyl peptidase IV (DPP-IV) inhibitors. These inhibitors play a crucial role in the treatment or prevention of diabetes by regulating the levels of glucose in the body. DPP-IV inhibitors help maintain a balance between the hormones responsible for glucose regulation, thus managing blood sugar levels effectively.

Upstream product

• 657428-42-7 4,6-dihydro-1H-pyrrolo[3,4-c]pyrazole-5-carboxylic acid tert-butyl ester 
• 124-63-0 methanesulfonyl chloride 
• 1226781-82-3 tert-butyl 2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate 
• 1280210-79-8 2,6-dihydropyrrole [3,4-c]pyrazole-5(4H)-carboxylic acid tert-butyl ester 

Downstream Products

• 1226781-88-9 tert-Butyl {(2R,3S,5R)-2-(2,4,5-Trifluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-yl}carbamate 
• 1226781-87-8 tert-butyl {(2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-yl}carbamate 
• 1350651-99-8 (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]oxepan-3-amine trifluoroacetate 
• 1548337-32-1 C₂₃H₂₇F₂N₅O₅S 
• 1548337-36-5 C₂₂H₂₅F₂N₅O₃ 
• 1350652-05-9 (2R,3S,5R)-2-(2,5-difluorophenyl)-5-[2-(methylsulfonyl)-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4H)-yl]thiepan-3-amine trifluoroacetate 

Relevant articles and documents

Design, Synthesis, and Evaluation of a Series of Novel Super Long-Acting DPP-4 Inhibitors for the Treatment of Type 2 Diabetes

In the present work, a novel series of trifluoromethyl-substituted tetrahydropyran derivatives were rationally designed and synthesized as potent DPP-4 inhibitors with significantly improved duration time of action over current commercially available DPP-4 inhibitors. The incorporation of the trifluoromethyl group on the 6-position of the tetrahydropyran ring of omarigliptin with the configuration of (2R,3S,5R,6S) not only significantly improves the overall pharmacokinetic profiles in mice but also maintains comparable DPP-4 inhibition activities. Further preclinical development of compound 2 exhibited its extraordinary efficacy in vivo and good safety profile. Clinical studies of compound 2 (Haisco HSK7653) are now ongoing in China, which revealed that inhibitor 2 could serve as an efficient candidate with a once-biweekly therapeutic regimen.

Amino six member ring derivatives and their use in medicine (by machine translation)

The invention relates to a six-member ring amino derivatives and its application in medicine, specifically relates to the general formula (I) as shown by the six-member ring of the amino derivative or its stereoisomer, pharmaceutically acceptable salt, prodrug, pharmaceutical composition containing the derivative of the dipeptidyl peptidase IV and the preparation (dPP CGI-iV) inhibitors of their medical use, wherein the general formula (I) definition of each substituent in the definition of the description of the same. (by machine translation)

Preparation method for 2-formyl chloride-2,4,5,6-tetrahydropyrrole[3,4-c]pyrazole benzene sulfonate

The invention discloses a preparation method for 2-formyl chloride-2,4,5,6-tetrahydropyrrole[3,4-c]pyrazole benzene sulfonate. The preparation method comprises the following steps: (1) adding a solvent A and dimethyl formamide-dimethyl adipate (DMF-DMA) i